These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37925066)

  • 1. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
    Gunter SJ; Kim EJ
    J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A; Smith JS; Larocca C
    J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
    Muszbek N; Remak E; Xin Q; McNamara L; Jones T
    J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
    [No Abstract]   [Full Text] [Related]  

  • 10. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
    Joshi TP; Duvic M
    J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
    [No Abstract]   [Full Text] [Related]  

  • 11. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
    Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
    J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations.
    Lewis DJ; Rook AH
    Int J Dermatol; 2021 Sep; 60(9):e362-e364. PubMed ID: 33559132
    [No Abstract]   [Full Text] [Related]  

  • 13. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I; Reneau JC; Hanel W; Chung CG
    Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
    J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous T-cell lymphoma and atopy: is there an association?
    Mehrany K; El-Azhary RA; Bouwhuis SA; Pittelkow MR
    Br J Dermatol; 2003 Nov; 149(5):1013-7. PubMed ID: 14632807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycosis fungoides and Sézary syndrome - Review and outlook.
    Latzka J; Trautinger F
    J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
    Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
    Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
    Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
    J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
    Albrecht JD; Nicolay JP
    Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.